Filament Health, a wholly owned subsidiary of Rhelion Life Sciences, has received a new Canadian patent covering PEX010, the company’s natural psilocybin drug candidate. The patent adds to Filament Health’s extensive global intellectual-property portfolio for natural psilocybin. Psilocybin is a psychedelic compound found in certain fungi. The announcement concerns TRUFF stock.